NO-Independent Vasodilation to Acetylcholine in the Rat Isolated Kidney Utilizes a Charybdotoxin-Sensitive, Intermediate-Conductance Ca++-Activated K+ Channel1

  1. P. Mieyal1,
  2. D. Fulton1,
  3. J.C. McGiff1 and
  4. J. Quilley2
  1. 1Department of Pharmacology (P.M., D.F., J.C.Mc.), New York Medical College, Valhalla, New York, and 2Department of Cell Biology (J.Q.), University of Medicine and Dentistry of New Jersey, School of Osteopathic Medicine, Stratford, New Jersey
     
    Next Section

    Abstract

    The role of K+ channels in the nitric oxide-independent renal vasodilator effect of acetylcholine (Ach) was examined to address the hypothesis that the mechanism underlying this response was different from that of bradykinin, because an earlier study indicated the possibility of different mediators. We used the rat isolated, perfused kidney that was constricted with phenylephrine and treated with nitroarginine and indomethacin to inhibit nitric oxide synthase and cyclooxygenase, respectively. The nonspecific K+channel inhibitors, procaine and tetraethylammonium (TEA), reduced vasodilator responses to Ach and cromakalim, but not those to nitroprusside. Glibenclamide, an inhibitor of ATP-sensitive K+ channels, reduced vasodilator responses to cromakalim but did not affect those to Ach or nitroprusside. Charybdotoxin, an inhibitor of Ca++-activated K+ channels, reduced vasodilator responses to Ach without affecting those to cromakalim or nitroprusside. Iberiotoxin and apamin, inhibitors of large- and small-conductance Ca++-activated K+channels, respectively, did not reduce vasodilation induced by Ach, cromakalim or nitroprusside. The inhibitor of cytochrome P450, clotrimazole, reduced the renal vasodilator effects of Ach and bradykinin but not those of nitroprusside or SCA 40, an agonist for Ca++-activated K+ channels. These results suggest that in the rat kidney, Ach, like bradykinin, utilizes a charybdotoxin-sensitive Ca++-activated K+channel of intermediate conductance to elicit vasodilation and that this effect may be dependent on cytochrome P450 activity.

    Endothelium-dependent vasodilation using Ach as the gold standard has generally been attributed to the release of NO. However, depending on the agonist, species, tissue and experimental conditions, NO-independent vasodilation can be demonstrated (Cowan and Cohen, 1991; Baydoun and Woodward, 1991; Nagao et al., 1992; Pacicca et al., 1992), a phenomenon attributed to the release of an endothelium-derived hyperpolarizing factor (EDHF), a term coined byTaylor and Weston (1988). In large conduit vessels such as the aorta, endothelium-dependent relaxation appears to be mediated solely by NO; responses can be abolished by inhibition of NOS (Palmer et al., 1988; Rees et al., 1989). In smaller vessels, the contribution of EDHF becomes more apparent, and endothelium-dependent vasodilation persists in the face of inhibition of NOS (Shimokawaet al., 1996). Thus, NO-independent vasodilation has been reported for Ach and bradykinin, although the identity of the mediator(s) and the type of K+ channel that is involved remain to be elucidated. Our studies using the rat heart and kidney strongly suggest a P450-dependent eicosanoid as the mediator of the vasodilator effect of bradykinin that persists in the presence of inhibitors of NOS and cyclooxygenase (Fulton et al., 1992,1995). This NO-independent effect is dependent on phospholipase C and A2 and is susceptible to inhibitors of P450 and K+ channels (Fulton et al., 1994, 1995, 1996), which suggests an endothelium-derived P450-dependent metabolite of arachidonic acid as a hyperpolarizing factor. This concept is supported by several recent reports (Hecker et al., 1994; Bauersachset al., 1994), and Campbell et al. (1996) have proposed epoxides as hyperpolarizing factors in bovine coronary arteries, on the basis of a comprehensive series of studies. However, it is possible that there are several hyperpolarizing factors, depending on the agonist, species and vascular tissue.

    In the rat kidney, we found that the vasodilator effect of Ach, as well as that of bradykinin, exhibited a substantial component that was unaffected by inhibition of NOS (Fulton et al., 1992). In this study, the renal vasodilator response to Ach, unlike that to bradykinin, was unaffected by inhibitors of P450, clotrimazole and 7-ethoxyresorufin, which suggests the possibility that a P450 product was not involved in this action of Ach (Fulton et al., 1992). These observations suggested, therefore, that the mediator of the NO-independent response to Ach was not the same as that mediating the response to bradykinin. Because the NO- and prostaglandin-independent renal and coronary vasodilator effects of bradykinin were dependent on activation of K+ channels, specifically charybdotoxin-sensitive K+ channels, the primary aim of the present study was to determine whether Ach-induced vasodilation used a similar mechanism, the premise being that a different mediator may use a different mechanism. Consequently, we first determined the role of K+ channels in the renal vasodilator action of Ach and then characterized the type of K+ channel. The initial experiments utilized nonspecific antagonists of K+ channels, and subsequent experiments investigated the contribution of ATP-sensitive K+ channels and of small-, intermediate- and large-conductance Ca++-activated K+ channels. Thus, studies addressing the type of K+ channel involved in NO-independent vascular responses that are attributed to EDHF have yielded variable results. Both small- and large-conductance Ca++-activated K+ channels (Cowan et al., 1993; Adeagbo and Triggle, 1993; Hecker et al., 1994) and, in a few instances, ATP-sensitive K+ channels (Standen et al., 1989) have been implicated, depending on the tissue. Recently, Zygmunt et al. (1997) proposed that a subtype of a small-conductance Ca++-activated K+ channel figures in the response to Ach in rat hepatic artery.

    The results of the present study show that the renal vasodilator effect of Ach in the presence of inhibitors of NOS and cyclooxygenase is dependent on activation of K+ channels, specifically charybdotoxin-sensitive Ca++-activated K+channels. Because the renal vasodilator effects of Ach and bradykinin exhibited similar characteristics in terms of the contribution of K+ channels, thereby suggesting a common mediator, we subsequently conducted additional studies with clotrimazole to investigate a potential role of P450 in the vasodilator action of Ach when NOS and cyclooxygenase were inhibited. Thus, earlier experiments suggested the possibility that the NO-independent renal vasodilator responses to Ach and bradykinin utilized different mediators. The present results show that the renal vasodilator effect of Ach is attenuated by clotrimazole.

    Previous SectionNext Section

    Materials and Methods

    The isolated perfused kidney of the rat has been described previously (Fulton et al., 1992; Rapacon et al., 1996). Briefly, after pentobarbitone anesthesia (65 mg/kg i.p.), the right kidney was exposed via a midline laparotomy. The right renal artery was cannulated via the mesenteric artery to avoid interruption of blood flow to the kidney, which was perfused at constant flow with oxygenated Krebs’ buffer (37°C) containing indomethacin (2.8 μM) using a pulsatile pump (Watson-Marlow, 502S). The vena cava was ligated above and below the right renal vein and cut for exit of the perfusate, and the right ureter was transected. Perfusate flow rate (8–10 ml/min), which was maintained constant throughout the experiment, was adjusted to obtain a basal perfusion pressure of approximately 65 to 85 mmHg, and nitroarginine (50 μM) was added to the perfusate to inhibit NO synthesis and isolate the NO-independent component of the vasodilator effect of Ach (Fultonet al., 1992). This concentration of nitroarginine was shown by Cachofeiro and Nasjletti (1991) to prevent increases in cGMP release from the kidney in response to bradykinin, and we found that doubling the concentration to 100 μM produced no further inhibition of renal vasodilator responses to Ach or bradykinin (Fulton et al., 1992). Inhibitors of K+ channels were added to the perfusate at least 10 min before vascular tone was elevated with phenylephrine (0.2–0.4 μM) that was titrated to raise perfusion pressure to about 180 to 200 mmHg to amplify vasodilator responses. Successive doses of Ach were added at intervals of at least 5 min and not before perfusion pressure had returned to the control value after the preceding dose. Once a stable elevated perfusion pressure was obtained, vasodilator responses to Ach (10–100 ng) were determined as maximal reductions in perfusion pressure. In the first series of experiments, responses to Ach were obtained under control conditions (n = 8) and in the presence of procaine (1 mM;n = 3) and TEA (10 mM; n = 3) to inhibit all types of K+ channels and of glibenclamide (10 μM; n = 4) to inhibit ATP-sensitive K+channels. Responses to cromakalim (3 μg), an activator of ATP-dependent K+ channels, and to nitroprusside (1 μg) were used as indices of the effectiveness of K+ channel blockade and vascular effects unrelated to inhibition of K+channels, respectively. The control group was the same for each of these interventions; 3 to 4 preparations a day were completed, where at least one was a control.

    In the second series of experiments, the role of Ca++-activated K+ channels was investigated by comparing vasodilator responses to Ach (30 and 100 ng) in the presence (n = 5) and absence (n = 4) of charybdotoxin at a concentration (10 nM) that markedly reduced renal vasodilator responses to bradykinin without affecting those to cromakalim or nitroprusside.

    In the third series of experiments, we investigated the contribution of large-conductance Ca++-activated K+ channels to the renal vasodilator effect of Ach, on the basis of the results with charybdotoxin, which inhibits both intermediate- and large-conductance Ca++-activated K+ channels. Thus, responses to Ach (30 and 300 ng) were determined in the presence (n= 6) and absence (n = 5) of iberiotoxin (10–50 nM). The doses of Ach represent an intermediate dose and a maximal dose that were used in anticipation of inhibition of the vasodilator effect by iberiotoxin.

    In a fourth series of experiments, the role of small-conductance Ca++-activated K+ channels was addressed by comparing responses to Ach (10–100 ng) in the presence (n = 4) and absence (n = 4) of apamin (250 nM).

    In the final series of experiments, vasodilator responses to Ach (30 and 100 ng) were determined in phenylephrine-constricted kidneys in the absence and presence of clotrimazole (1 μM) to inhibit P450. Clotrimazole was included in the perfusate from the start of the experiment. Responses to a single dose of bradykinin were also assessed; we reported previously that clotrimazole attenuated the renal vasodilator effect of this peptide. Responses to SCA 40, an agent reported to stimulate Ca++-activated K+channels (Laurent et al., 1993), and nitroprusside were used to assess any effects of clotrimazole on vasodilator responses mediatedvia activation of K+ channels and guanylate cyclase, respectively. SCA 40 was used in these experiments, because clotrimazole has been reported to affect the function of Ca++-activated K+ channels (Alvarez et al., 1992).

    Statistical analysis.

    Data from the various groups were compared by ANOVA and individual points by Newman-Keuls test.P < .05 was considered statistically significant.

    Materials.

    Indomethacin, nitroarginine, procaine, TEA, glibenclamide, Ach, cromakalim, apamin and sodium nitroprusside were obtained from Sigma Chemical Co. (St. Louis, MO), and charybdotoxin and iberiotoxin were obtained from Peptides International (Louisville, KY). Indomethacin was dissolved in 4.2% NaHCO3, glibenclamide and cromakalim were dissolved in ethanol and the other compounds were dissolved in saline or distilled water.

    Previous SectionNext Section

    Results

    Basal perfusion pressures (65–85 mmHg) were not different between the various groups treated with K+ channel inhibitors.

    Nonspecific inhibition of K+ channels.

    Elevated perfusion pressure in the control group was 189 ± 4 mmHg compared with 165 ± 10 mmHg for the procaine group and 190 ± 5 mmHg for the TEA-treated group. Ach elicited dose-dependent vasodilation in phenylephrine-constricted kidneys in which NO and prostaglandin synthesis was inhibited (figs. 1 and 2). Thus 10, 30 and 100 ng of Ach reduced perfusion pressure by 6 ± 3, 25 ± 5 and 46 ± 8 mmHg, respectively. Procaine and TEA greatly reduced the vasodilator effect of cromakalin (fig. 2), a result that shows their effectiveness against K+ channels. These inhibitors abolished the NO-independent vasodilator action of Ach, which indicates that K+ channels play a role in the response. TEA also reduced the vasodilator effect of nitroprusside (P < .05), which suggests effects other than inhibition of K+ channels.

    ATP-sensitive K+ channels.

    Elevated perfusion pressure in the glibenclamide-treated group was 184 + 9 mmHg compared with 189 + 4 mmHg in the control group, a value the same as that in the procaine and TEA experiments. The vasodilator effect of cromakalim was abolished by glibenclamide (fig. 3), which shows that this agent blocked ATP-sensitive K+ channels. However, vasodilator responses to Ach were unaffected by glibenclamide, a result that excludes a role for ATP-sensitive K+ channels. Responses to nitroprusside were also unaffected by glibenclamide, which provides evidence for its specificity.

    Ca++-activated K+ channels.

    Elevated perfusion pressure in the charybdotoxin-treated group was 189 ± 4 compared with 177 ± 9 in the respective control group. In the control group, 30 and 100 ng of Ach lowered perfusion pressure by 28 ± 5 and 39 ± 7 mmHg, respectively (fig. 4), compared with 3 ± 2 and 12 ± 3 mmHg, respectively, in the presence of charydotoxin; this indicates a role for Ca++-activated K+channels. In contrast, charybdotoxin had no effect on vasodilator responses to cromakalim or nitroprusside, a reflection of its specificity.

    Whether large-conductance Ca++-activated K+channels play a role was addressed using the specific inhibitor, iberiotoxin. Elevated perfusion pressure in the iberiotoxin-treated group was 203 ± 7 vs. 191 ± 4 in the respective control group. In the control group, 30 and 300 ng of Ach reduced perfusion pressure by 27 ± 2 and 55 ± 5 mmHg, respectively, responses that were unaffected by iberiotoxin at concentrations ranging from 10 to 50 nM. Consequently, the data from experiments using different concentrations of iberiotoxin were pooled. Responses to 30 and 300 ng of Ach in the combined group were 30 ± 2 and 67 ± 5 mmHg, respectively. Because iberiotoxin had no effect on responses to Ach, nonspecific effects were not addressed.

    We examined whether small-conductance Ca++-activated K+ channels play a role by using apamin. Elevated perfusion pressure in the apamin-treated group was 200 ± 5 mmHgvs. 197 ± 3 mmHg in the control group, in which 10, 30 and 100 ng of Ach reduced perfusion pressure by 10 ± 1, 23 ± 3 and 41 ± 2 mmHg, respectively, compared with 23 ± 4, 26 ± 2 and 60 ± 3 mmHg, respectively, in the apamin-treated group. Responses to nitroprusside were not different in the control and apamin groups (63 ± 11 vs. 70 ± 9 mmHg), whereas responses to cromakalim (5 μg) were slightly greater with apamin treatment (72 ± 1 vs. 53 ± 7 mmHg).

    Inhibition of P450.

    The results with the K+channel inhibitors suggested that Ach utilizes a type of channel similar to that used by bradykinin (Fulton et al., 1994). Consequently, we questioned whether these endothelium-dependent vasodilators use different mediators, a proposal based on an earlier study in which the vasodilator effect of bradykinin was reduced by inhibitors of P450, whereas that of Ach was unaffected (Fulton et al., 1992). In those experiments, NO and prostaglandin synthesis were intact. Therefore, we conducted experiments in nitroarginine- and indomethacin-treated kidneys to determine the effects of the P450 inhibitor clotrimazole on responses to Ach.

    Phenylephrine elevated perfusion pressure from 74 ± 3 mmHg to 223 ± 5 mmHg in the clotrimazole-treated group (n= 4) and from 76 ± 6 to 214 ± 4 mmHg in the control group (n = 5). In clotrimazole-treated kidneys, responses to Ach were approximately 50% of those obtained in the control group (fig. 5), which suggests a role for P450. As previously reported, the vasodilator effect of bradykinin was also reduced by clotrimzole, whereas responses to nitroprusside and SCA 40 were unaffected (fig. 5).

    Previous SectionNext Section

    Discussion

    In the rat perfused kidney, the vasodilator effect of bradykinin exhibits three components subserved by NO and P450 with a lesser contribution of prostaglandins, a conclusion based on the use of inhibitors of these pathways (Fulton et al., 1992). Similarly, in the rat heart, the endothelium-dependent vasodilator effect of bradykinin, which was independent of NO, was susceptible to inhibitors of P450, phospholipases and K+ channels (Fultonet al., 1994, 1995, 1996); this suggests that a P450-dependent metabolite of arachidonic acid exhibited the essential properties of EDHF. As with the heart, the renal vasodilator action of bradykinin involved a charybdotoxin-sensitive K+ channel (Rapacon et al., 1996). In the studies of bradykinin in the kidney, we also noted that a vasodilator effect of Ach could be demonstrated in the presence of an inhibitor of NO synthesis (Fultonet al., 1992), a finding supported by Vargas et al. (1994). However, in the absence of inhibitors of NOS and cyclooxygenase, the vasodilator response to Ach, unlike that to bradykinin, was not affected by the inhibitors of P450, clotrimazole and 7-ethoxyresorufin (Fulton et al., 1992). Because NO-independent responses to Ach have been attributed to the release of EDHF, these results suggest the possibility that bradykinin and acetylcholine utilize different hyperpolarizing factors. Consequently, the primary aim of the present study was to examine whether Ach and bradykinin use different mechanisms to elicit NO-independent renal vasodilation. The experimental approach was threefold: 1) to determine whether K+ channels contribute to the action of acetylcholine, 2) to examine whether Ach and bradykinin utilize a similar type of K+ channel and 3) to assess whether the vasodilator activity of Ach could be distinguished from that of bradykinin in terms of a P450 component using clotrimazole. We used clotrimazole in this series of experiments because it was one of the agents used in previous studies with bradykinin (Fulton et al., 1992). Moreover, clotrimazole, like other imidazoles, may have a more selective action on the formation of epoxides (Zou et al., 1994) that exhibit some of the properties required of an EDHF. Although the imidazole derivatives have been reported to elicit effects that may be unrelated to inhibition of P450, our experiments show that clotrimazole had no effect on vasodilator responses to nitroprusside and SCA 40, which indicates that, under these experimental conditions, it did not affect vasodilation mediated by NO or activation of K+ channels.

    The results of this study demonstrate that the NO- and prostaglandin-independent component of the renal vasodilator effect of Ach, which was isolated by inhibition of NO and prostaglandin synthesis and amplified by elevation of vascular tone, utilizes a mechanism similar to that of bradykinin in the rat heart and kidney—i.e., stimulation of Ca++-activated K+ channels. Thus, TEA and procaine, at concentrations that greatly reduced the vasodilator effect of cromakalim by inhibiting ATP-sensitive K+ channels, abolished the renal vasodilator action of Ach. The lack of effect of glibenclamide, at a concentration that abolished responses to cromakalim, on vasodilator responses to Ach excluded a role for ATP-sensitive K+ channels; this was also true of bradykinin (Fulton et al., 1994). In contrast, the potent inhibitory effect of charybdotoxin is presumptive evidence of a role for Ca++-activated K+ channels in the vasodilator effect of Ach. The specificity of the action of charybdotoxin is supported by the lack of effect on vasodilator responses to cromakalim and nitroprusside. Charybdotoxin is considered to be more selective for large-conductance Ca++-activated K+ channels, although, depending on the source and type of tissue, the actions of charybdotoxin may not be limited to this type of channel (Kuriyama et al., 1995) but may also affect intermediate-conductance Ca++-activated K+channels and delayed rectifier-type K+ channels (Kaczorowski et al., 1996).

    In vascular smooth muscle, various subtypes of Ca++-activated K+ channels have been identified and include large-, intermediate- and small-conductance channels (Kuriyama et al., 1995). Consequently, we also used iberiotoxin to inhibit large-conductance Ca++-activated K+ channels. The lack of effect of iberiotoxin on vasodilator responses to Ach tends to exclude large-conductance channels that are generally considered to be sensitive to charybdotoxin (Kuriyama et al., 1995). However, it is possible that subtypes of large-conductance Ca++-activated K+channels exist that exhibit differential sensitivity to charybdotoxin and iberiotoxin. Alternatively, an insufficient concentration of iberiotoxin may have been used, although this is unlikely because the concentrations up to 50 nM that we employed are far in excess of the concentration shown to inhibit large-conductance Ca++-activated K+ channels (Galvez et al., 1990). The results with iberiotoxin coupled with those with charybdotoxin, which does not inhibit small-conductance channels, suggest by exclusion that Ach, like bradykinin, utilizes an intermediate-conductance Ca++-activated K+channel to elicit NO-independent renal vasodilation (Rapacon et al., 1996). Moreover, a role for small-conductance Ca++-activated K+ channels was excluded because apamin did not reduce the renal vasodilator response to Ach; rather, it tended to increase it. These results contrast with those of Zygmuntet al. (1997), who reported that neither apamin alone nor charybdotoxin alone affected responses to Ach in rings of hepatic artery. Thus, a combination of apamin and charybdotoxin was necessary to inhibit the effect of Ach, and Zygmunt et al. (1997)proposed a subtype of a small-conductance channel as the target for EDHF. Our results indicate the involvement of an intermediate-conductance Ca++-activated K+channel; neither iberiotoxin nor apamin reduced responses to Ach, whereas charybdotoxin alone markedly reduced the vasodilator effect of Ach. However, we cannot exclude a role for voltage-dependent K+ channels, because charybdotoxin also inhibits some subtypes of these channels (Kaczorowski et al., 1996).

    Unlike the results of an earlier study showing that the vasodilator response to Ach was unaffected by inhibitors of P450 (Fulton et al., 1992), the results of the present study show that clotrimazole attenuated the renal vasodilator effect of Ach to a similar extent to that seen with bradykinin. The different results observed in these two studies are not readily explained, although the experimental conditions were not identical. In the current investigation, the effect of clotrimazole was assessed in the presence of nitroarginine and indomethacin, whereas all vasodilator mechanisms were intact in the earlier study. Thus, it may be that when one system is compromised, another mechanism can elicit a full vasodilator response. Second, in the earlier study, only one dose of Ach was tested. Nonetheless, it is difficult to reconcile the previous observations of a differential effect of clotrimazole on the responses to bradykinin and Ach with the current results: a similar inhibitory action on responses to bradykinin and Ach unless the responses are unequally dependent on two or more mediators. The effects of clotrimazole could not be attributed to actions on vasodilator mechanisms in general or to actions on K+ channels, because dilator responses to nitroprusside and SCA 40, respectively, were unaffected, a result consistent with our previous observations. Thus, these findings indicate that the vasodilator effect of Ach, like that of bradykinin, exhibits a substantial NO-independent component that depends on P450 and on activation of Ca++-activated K+ channels.

    Another interpretation of the results is that charydotoxin blocks a Ca++-activated K+ channel in the endothelium that is stimulated by both Ach and bradykinin and results in the release of vasodilator mediators. Thus, endothelial cells possess channels that can be inhibited by TEA and charybdotoxin (Rusko et al., 1992). The use of an isolated organ to address hyperpolarization as a mechanism of Ach-induced vasodilation is limited because it is not possible to measure the membrane potential of endothelial and smooth muscle cells in resistance vessels. Thus, studies of this nature rely on the use of pharmacological agents that can potentially interfere at more than one step in the signal transduction pathway—in this case, at the level of the endothelium rather than the smooth muscle.

    In summary, we have shown that the NO-independent renal vasodilator effect of Ach, like that of bradykinin, is mediated viaCa++-activated K+ channels, presumably of intermediate conductance, and may involve the participation of a P450-related mechanism.

    Previous SectionNext Section

    Footnotes

    • Send reprint requests to: J. Quilley, Dept. of Cell Biology, UMDNJ, Stratford, NJ 08084.

    • ↵1 This work was supported by NIH grants HL 49275, HL 25394 and AHA grant 940-318.

    • Abbreviations:
      Ach
      acetylcholine
      NO
      nitric oxide
      NOS
      nitric oxide synthase
      EDHF
      endothelium-derived hyperpolarizing factor
      P450
      cytochrome P450
      TEA
      tetraethylammonium
      • Received June 23, 1997.
      • Accepted January 20, 1998.
    Previous Section
     

    References

    1. ↵
      1. Adeagbo ASO,
      2. Triggle CR
      (1993) Varying extracellular K+: A functional approach to separating EDHF and ENDO-related mechanisms in perfused rat mesenteric arterial bed. J Cardiovasc Pharmacol 21:423–429.
      MedlineWeb of Science
    2. ↵
      1. Alvarez J,
      2. Montero M,
      3. Garcia-Sanchez J
      (1992) High affinity inhibition of Ca2+-dependent K+ channels by cytochrome P450 inhibitors. J Biol Chem 267:11789–11793.
      Abstract/FREE Full Text
    3. ↵
      1. Bauersachs J,
      2. Hecker M,
      3. Busse R
      (1994) Display of the characteristics of endothelium-derived hyperpolarising factor by a cytochrome P450-derived arachidonic acid matabolite in the coronary microcirculation. Br J Pharmacol 113:1548–1553.
      MedlineWeb of Science
    4. ↵
      1. Baydoun AR,
      2. Woodward B
      (1991) Effects of bradykinin in the rat isolated perfused heart: Role of kinin receptors and endothelium-derived relaxing factor. Br J Pharmacol 103:1829–1833.
      MedlineWeb of Science
    5. ↵
      1. Cachofeiro V,
      2. Nasjletti A
      (1991) Increased vascular responsiveness to bradykinin in kidneys of spontaneously hypertensive rats. Effect of N-ω-nitro-l-arginine. Hypertension 18:683–688.
      Abstract/FREE Full Text
    6. ↵
      1. Campbell WB,
      2. Gebremedhin D,
      3. Pratt PF,
      4. Harder DR
      (1996) Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarising factors. Circ Res 78:415–423.
      Abstract/FREE Full Text
    7. ↵
      1. Cowan CL,
      2. Cohen RA
      (1991) Two mechanisms mediate relaxation by bradykinin of pig coronary artery: NO-dependent and -independent responses. Am J Physiol 261:H830–H835.
      Abstract/FREE Full Text
    8. ↵
      1. Cowan CL,
      2. Palacino JJ,
      3. Najibi S,
      4. Cohen RA
      (1993) Potassium-channel-mediated relaxation to acetylcholine in rabbit arteries. J Pharmacol Exp Ther 266:1482–1489.
      Abstract/FREE Full Text
    9. ↵
      1. Fulton D,
      2. McGiff JC,
      3. Quilley J
      (1992) Contribution of NO and cytochrome P450 to the vasodilator effect of bradykinin in the rat kidney. Br J Pharmacol 107:722–725.
      MedlineWeb of Science
    10. ↵
      1. Fulton D,
      2. Mahboubi K,
      3. McGiff JC,
      4. Quilley J
      (1995a) Cytochrome P450-dependent effects of bradykinin in the rat heart. Br J Pharmacol 114:99–102.
      MedlineWeb of Science
    11. ↵
      1. Fulton D,
      2. McGiff JC,
      3. Quilley J
      (1996) Role of phospholipase C and phospholipase A2 in the nitric oxide-independent vasodilator effect of bradykinin in the rat perfused heart. J Pharmacol Exp Ther 278:518–526.
      Abstract/FREE Full Text
    12. ↵
      1. Fulton D,
      2. McGiff JC,
      3. Quilley J
      (1994) Role of K+ channels in the vasodilator response to bradykinin in the rat heart. Br J Pharmacol 113:954–958.
      MedlineWeb of Science
    13. ↵
      1. Galvez A,
      2. Gimenez-Gallego G,
      3. Reuben JP,
      4. Roy-Contancin L,
      5. Feigenbaum P,
      6. Kaczorowski GJ,
      7. Garcia ML
      (1990) Purification and characterisation of a unique, potent, peptidyl probe for the high conductance calcium-activated potassium channel from the venom of the scorpion Buthus tamalus. J Biol Chem 265:10083–10090.
    14. ↵
      1. Hecker M,
      2. Bara AT,
      3. Bauersachs J,
      4. Busse R
      (1994) Characterisation of endothelium-derived hyperpolarising factor as a cytochrome P450-derived arachidonic acid metabolite in mammals. J Physiol 481:407–414.
      Abstract/FREE Full Text
    15. ↵
      1. Kaczorowski GJ,
      2. Knaus HG,
      3. Leonard RJ,
      4. McManus OB,
      5. Garcia ML
      (1996) High conductance calcium-activated potassium channels: Structure, pharmacology and function. J Bioenerg Biomembr 28:255–267.
      CrossRefMedlineWeb of Science
    16. ↵
      1. Kuriyama H,
      2. Kitamura K,
      3. Nabata H
      (1995) Pharmacological and physiological significance of ion channels and factors that modulate them in vascular tissues. Pharmacol Rev 47:387–573.
      MedlineWeb of Science
    17. ↵
      1. Laurent F,
      2. Michel A,
      3. Chapat JP,
      4. Boucard M
      (1993) Evaluation of the relaxant effects of SCA 40, a novel charybdotoxin-sensitive potassium channel opener in guinea pig isolated trachealis. Br J Pharmacol 108:622–626.
      MedlineWeb of Science
    18. ↵
      1. Nagao T,
      2. Illiano S,
      3. Vanhoutte PM
      (1992) Heterogeneous distribution of endothelium-dependent relaxations resistant to NG-nitro-l-arginine in rats. Am J Physiol 263:H1090–H1094.
      Abstract/FREE Full Text
    19. ↵
      1. Pacicca C,
      2. von der Weid PY,
      3. Beny JL
      (1992) Effect of nitro-l-arginine on endothelium-dependent hyperpolarisations and relaxations of pig coronary arteries. J Physiol (Lond.) 457:247–256.
      Abstract/FREE Full Text
    20. ↵
      1. Palmer RM,
      2. Rees DD,
      3. Ashton DS,
      4. Moncada S
      (1988) l-Arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun 153:1251–1256.
      CrossRefMedlineWeb of Science
    21. ↵
      1. Rapacon M,
      2. Mieyal P,
      3. McGiff JC,
      4. Fulton D,
      5. Quilley J
      (1996) Contribution of Ca++-activated K+ channels to the vasodilator effect of bradykinin in the isolated, perfused kidney of the rat. Br J Pharmacol 118:1504–1508.
      MedlineWeb of Science
    22. ↵
      1. Rees DD,
      2. Palmer RM,
      3. Hodson HF,
      4. Moncada S
      (1989) A specific inhibitor of nitric oxide formation from l-arginine attenuates endothelium-dependent relaxation. Br J Pharmacol 96:418–424.
      MedlineWeb of Science
    23. ↵
      1. Rusko J,
      2. Tanzu F,
      3. Van Bremen C,
      4. Adams DJ
      (1992) Calcium-activated potassium channels in native endothelial cells from rabbit aorta: Conductance, Ca2+ sensitivity and block. J Physiol 455:601–621.
      Abstract/FREE Full Text
    24. ↵
      1. Shimokawa H,
      2. Yatsutake H,
      3. Gujii K,
      4. Owada MK,
      5. Nakaike R,
      6. Fukumoto Y,
      7. Takayanagi T,
      8. Nagao T,
      9. Egashira K,
      10. Fujishima M,
      11. Takeshita A
      (1996) The importance of the hyperpolarising mechanism increases as the vessel size decreases in endothelium-dependent relaxations in rat mesenteric circulation. J Cardiovasc Pharmacol 28:703–711.
      CrossRefMedlineWeb of Science
    25. ↵
      1. Standen NB,
      2. Quayle JM,
      3. Davis NW,
      4. Brayden JE,
      5. Huang Y,
      6. Nelson TM
      (1989) Hyperpolarizing vasodilators activate ATP-sensitive potassium channels in arterial smooth muscle. Science (Wash DC) 245:177–180.
      Abstract/FREE Full Text
    26. ↵
      1. Taylor SG,
      2. Weston AH
      (1988) Endothelium-derived hyperpolarising factor: A new endogenous inhibitor from the vascular endothelium. Trends Pharmacol Sci 9:272–274.
      CrossRefMedline
    27. ↵
      1. Vargas F,
      2. Sabio JM,
      3. Luna JD
      (1994) Contribution of endothelium-derived relaxing factors to acetylcholine-induced vasodilatation in the rat kidney. Cardiovasc Res 28:1373–1377.
      Abstract/FREE Full Text
    28. ↵
      1. Zou A-P,
      2. Imig JD,
      3. Kaldunski M,
      4. Ortiz de Montellano PR,
      5. Sui Z,
      6. Roman RJ
      (1994) Inhibition of renal vascular 20-HETE production impairs autoregulation of renal blood flow. Am J Physiol 266:F275–F282.
      Abstract/FREE Full Text
    29. ↵
      1. Zygmunt PM,
      2. Edwards G,
      3. Weston AH,
      4. Larsson B,
      5. Hogestatt ED
      (1997) Involvement of voltage-dependent potassium channels in EDHF-mediated relaxation of rat hepatic artery. Br J Pharmacol [6] 121:141–149.
    Figure 1
    View larger version:
    Figure 1

    Representative recording of perfusion pressure showing basal perfusion pressure, elevation of perfusion pressure with phenylephrine (arrow) and vasodilator responses to Ach and cromakalim (CK) in the rat isolated kidney treated with nitroarginine and indomethacin.

    Figure 2
    View larger version:
    Figure 2

    Effects of procaine (1 mM; n = 3) and TEA (10 mM; n = 3) on vasodilator responses to acetylcholine (Ach), cromakalim and nitroprusside (NP) in kidneys treated with nitroarginine and indomethacin and constricted with phenylephrine to elevate perfusion pressure (PP) to approximately 180 to 200 mmHg. *P < .05; **P < .01.

    Figure 3
    View larger version:
    Figure 3

    Vasodilator responses to acetylcholine (Ach), cromakalim and nitroprusside (NP) in the presence (open columns) and absence (solid columns) of glibenclamide (10 μM) in kidneys treated with nitroarginine and indomethacin and constricted with phenylephrine to elevate perfusion pressure (PP) to approximately 180 to 200 mmHg.

    Figure 4
    View larger version:
    Figure 4

    Vasodilator responses to acetylcholine (Ach), cromakalim and nitroprusside (NP) in the presence (open columns) and absence (solid columns) of charybdotoxin in kidneys treated with nitroarginine and indomethacin and constricted with phenylephrine to elevate perfusion pressure (PP) to approximately 180 to 200 mmHg. *P < .05; **P < .001.

    Figure 5
    View larger version:
    Figure 5

    Vasodilator responses to acetylcholine (Ach), bradykinin (BK), SCA 40 and nitroprusside in the presence (open columns) and absence (solid columns) of clotrimazole (1 μM) in kidneys treated with nitroarginine (50 μM) and indomethacin (2.8 μM) and constricted with phenylephrine (4 × 10−7M) to elevate perfusion pressure to approximately 200 mmHg.

    « Previous | Next Article »Table of Contents

    This Article

    1. JPET May 1, 1998 vol. 285 no. 2 659-664
    1. AbstractFree
    2. » Full Text
    3. Full Text (PDF)

    Responses

    1. Submit a response
    2. No responses published

    Navigate This Article

    Current Issue

    1. November 2009, 331 (2)
    1. Current Issue
    1. Alert me to new issues of JPET